Niagen Bioscience renamed its research program to align with company branding while expanding support for NAD+ science across 300+ collaborations and 45+ peer-reviewed human studies. The initiative now prioritizes clinical investigation into energy metabolism, cognitive function, cardiovascular health, and immune response through both oral and pharmaceutical-grade formulations.
Key Points
- Research program rebranded to Niagen Research Program with 300+ collaborations
- 45+ peer-reviewed human studies published; 175+ ongoing studies funded
- New focus areas: cellular energy, cognition, cardiovascular, immune function
Longevity Analysis
NAD+ availability declines with age and directly constrains cellular energy production, mitochondrial function, and the regenerative processes that sustain tissue repair and metabolic resilience. Systematic research into nicotinamide riboside supplementation across multiple physiological domains—from exercise adaptation to immune competence to cardiovascular function—provides the evidence base required to determine whether NAD+ repletion offers meaningful intervention points for age-related decline. The breadth of this research infrastructure, spanning academic centers and involving both preclinical and human clinical work, establishes the conditions necessary to decode individual responses to NAD+ support and to distinguish signal from marketing narrative.
Original published by LT Wire.